BATAVIA BIOSCIENCES BV

Their core work

Batavia Biosciences is a Dutch bioprocessing and contract development company based in Leiden, specializing in gene therapy product development and manufacturing services. Their H2020 participation covers two distinct disease areas — rare immunodeficiencies (SCID) and cardiovascular disease — both addressed through advanced gene therapy approaches. Their role as a participant in both RIA projects points to a specialist service provider function, contributing bioprocessing know-how, vector production, or analytical development to academic-led research consortia. With a website branded around bioservices, they sit at the interface between fundamental gene therapy research and the scalable manufacturing steps needed to bring therapies toward clinical development.

What they specialise in

How they've shifted over time

Their earliest H2020 work (RECOMB, starting 2018) focused tightly on gene therapy for a specific rare genetic disease — SCID — representing a classic rare-disease, high-unmet-need application. By 2019 they had expanded into cardiovascular disease with CardioReGenix, a much larger patient population, and simultaneously introduced ncRNA as an additional therapeutic modality. The trajectory is clear: starting from a narrow rare-disease gene therapy niche, they are broadening both the disease scope and the molecular toolkit, moving toward a more versatile gene therapy services position.

They are expanding from rare monogenic diseases into high-prevalence cardiovascular indications while adding ncRNA as a complementary therapeutic modality — a direction that significantly increases their commercial and collaborative surface area.

How they like to work

Batavia Biosciences has participated exclusively as a consortium partner, never as coordinator, across both projects — consistent with a specialist service provider that joins consortia to contribute specific technical capabilities rather than to lead research programs. Their two projects together brought them into contact with 28 unique partners across 10 countries, suggesting active and diverse engagement rather than passive involvement. This profile makes them a predictable, low-overhead partner for consortia that need a dedicated gene therapy processing or manufacturing node.

With 28 unique consortium partners across 10 countries from just 2 projects, Batavia Biosciences has built a surprisingly broad network relative to their small project count, indicating they participate in large multi-partner consortia. Their geographic reach spans at least 10 European countries, consistent with major EU health research consortia.

What sets them apart

Batavia Biosciences occupies a rare position as a Netherlands-based SME with direct hands-on involvement in both rare-disease and cardiovascular gene therapy programs — two of the highest-priority clinical gene therapy areas. Unlike university groups that generate IP, or large CROs that handle clinical trials, they appear to operate in the critical middle ground of process development and bioprocessing services, which is chronically underrepresented in EU consortia. For a consortium building a gene therapy project that needs a credible, experienced processing partner with a track record in EU-funded research, they represent a targeted and efficient choice.

Highlights from their portfolio

• RECOMB
  The larger of the two grants (€982,125) and the foundational project establishing their gene therapy credentials, targeting SCID — a serious rare disease with strong regulatory and patient advocacy interest.
• CardioReGenix
  Broadens their portfolio into cardiovascular disease and introduces ncRNA therapeutics, demonstrating strategic diversification from rare to common diseases and from one modality to two.